Amgen’s Bkemv Earns FDA Approval as First Interchangeable Biosimilar to Soliris

The FDA approved Amgen’s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca’s Soliris (eculizumab) to treat the rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).…

Continue ReadingAmgen’s Bkemv Earns FDA Approval as First Interchangeable Biosimilar to Soliris